Skip to content
Screener

Total Liabilities & Equity at other companies

BK
BKBK
$561.52B+27.4%
Schering-Plough logo
Schering-PloughSGP
$258.39M
GPA
General Purpose Acquisition Corp.GPAC
$9.44M-17.6%
Veradermics logo
VeradermicsMANE
$397.36M
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$3.5M
Dollar General logo
Dollar GeneralDG
$31.7B+2.3%

Other financials

Income statement

See full
Operating income-$26.1M-62.4%
Net income-$24.2M-97.8%
EPS (diluted)-$0.80+93.8%

Balance sheet

See full
Cash & equivalents$237.4M
Total debt$1.0M
Total equity$454.3M+421%
Total assets$467.8M

Cash flow

See full
Operating cash flow-$22.6M-47.6%
CapEx$23.0K
Free cash flow-$22.7M-47.8%

Valuation

See full
Market cap$2.32B+107%
Enterprise value$2.08B

Returns & leverage

See full
Return on equity-45.7%
Debt / equity
Current ratio35.8×

Where this comes from

Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344533
Line itemJune 30, 2026December 31, 2025
Ordinary shares, DKK 1 par value; no shares and 946,000 shares authorized, issued, and outstanding as of June 30, 2026 and December 31, 2025, respectively132
Common stock, $0.0001 par value; 400,000,000 shares and no shares authorized as of June 30, 2026 and December 31, 2025, respectively; 46,705,410 shares and no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively5
Preferred stock, $0.0001 par value; 5,000,000 shares and no shares authorized as of June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Additional paid-in capital685,7094,916
Accumulated deficit(228,695)(181,858)
Accumulated other comprehensive (loss) income(2,748)175
Total stockholders’ equity (deficit)454,271(176,635)
Total liabilities, convertible preference shares, convertible preferred stock and stockholders’ equity (deficit)$467,781$194,783

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Hemab Therapeutics Holdings, Inc.'s total liabilities & equity?
Hemab Therapeutics Holdings, Inc. (COAG) reported total liabilities & equity of $467.78M in Q2 2026.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Hemab Therapeutics Holdings, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude